Metabolic Dysfunction Associated Steatotic Liver DiseaseNCT07873749
Assessment of Circulating Leptin Levels in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
An observational study of Metabolic Dysfunction Associated Steatotic Liver Disease, run by Sohag University.
Trial summary
This study aims to evaluate circulating leptin levels in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Leptin is an adipokine involved in metabolism and inflammation. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Metabolic Dysfunction Associated Steatotic Liver Disease
- What is being tested?
- Serum Leptin Measurement
- How many people
- 96 participants
- Where
- No sites listed yet
- Study dates
- 15 Oct 2026to 15 Jun 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Patients attending the Gastroenterology and Hepatology outpatient clinics or inpatient departments at Sohag University Hospitals, along with healthy volunteers matched for age and sex.
Inclusion Criteria: Patient older than 18 years diagnosed with MASLD according to Delphi consensus criteria In addition to a control group of healthy individuals, matched to them in age, sex and number.
-
Exclusion Criteria: 1-Significant alcohol consumption (>20 g/day for females, >30 g/day for males).
2-Other causes of chronic liver disease:
- Viral hepatitis (HBV, HCV)
- Autoimmune hepatitis.
- Wilson's disease.
- Hemochromatosis.
- Drug-induced liver injury. 3-Active infection or acute inflammatory conditions. 4- Malignancy. 5-Pregnancy.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This study aims to evaluate circulating leptin levels in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Leptin is an adipokine involved in metabolism and inflammation. The study will assess the association between serum leptin levels and the presence or severity of MASLD compared to controls.
- Being tested
- Serum Leptin Measurement
- Keywords
- Leptin, Metabolic Dysfunction-Associated Steatotic Liver Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Serum Leptin MeasurementOther
evaluate circulating leptin levels in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
| Study group | Role | What they receive |
|---|---|---|
| MASLD Patient | Patients diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease Receives: Other: Serum Leptin Measurement | |
| Healthy controls | Not described Receives: Other: Serum Leptin Measurement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum Leptin Levels
Serum concentration of leptin measured in ng/mL using enzyme-linked immunosorbent assay (ELISA) in patients with MASLD compared to controls.
Measured: At baseline (upon study enrollment for each participant)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Oct 2026
- Study start15 Oct 2026 (estimated)
- Primary completion1 Feb 2027 (estimated)
- Study completion15 Jun 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metabolic Dysfunction Associated Steatotic Liver DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 96 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mayada Arfat Mohamed, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07873749
- Sponsor's protocol ID
- Soh-Med-26-7-34MS
- Status last verified
- Oct 2026
- First submitted
- 8 Oct 2026
- Last updated
- 14 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No